Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LifeTech Scientific's Enterprise Value is HK$4,758 Mil.
LifeTech Scientific's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$212 Mil. Therefore, LifeTech Scientific's EV-to-EBIT ratio for today is 22.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, LifeTech Scientific's Enterprise Value is HK$4,758 Mil.
LifeTech Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$224 Mil. Therefore, LifeTech Scientific's EV-to-EBITDA ratio for today is 21.24.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, LifeTech Scientific's Enterprise Value is HK$4,758 Mil.
LifeTech Scientific's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,505 Mil. Therefore, LifeTech Scientific's EV-to-Revenue ratio for today is 3.16.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
LifeTech Scientific (HKSE:01302) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$212 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$224 Mil.
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,505 Mil.
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$602 Mil.
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$437 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific Enterprise Value Related Terms
LifeTech Scientific Enterprise Value Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01302 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, LifeTech Scientific's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Enterprise Value distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
LifeTech Scientific's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$4,758 Mil mean?
LifeTech Scientific (HKSE:01302) has a Enterprise Value of HK$4,758 Mil as of Jul. 21, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on LifeTech Scientific and its competitors.
Is LifeTech Scientific's Enterprise Value too high?
LifeTech Scientific's current Enterprise Value is HK$4,758 Mil. Overall, LifeTech Scientific has a GF Score™ of 95/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Enterprise Value compare to ABT and SYK?
LifeTech Scientific's Enterprise Value of HK$4,758 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on LifeTech Scientific and its competitors. LifeTech Scientific's current Enterprise Value is HK$4,758 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
Based on GuruFocus' analysis, LifeTech Scientific (HKSE:01302) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.12, compared to a current price of HK$1.38 — trading 34.9% below its estimated fair value. The current Enterprise Value is HK$4,758 Mil. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For LifeTech Scientific (HKSE:01302), the current Enterprise Value is HK$4,758 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (HKSE:01302) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of HK$1.38 is trading 34.9% below its estimated GF Value™ of HK$2.12.
GuruFocus considers LifeTech Scientific to be Possible Value Trap.
Key valuation signals for HKSE:01302:
Enterprise Value: HK$4,758 Mil
GF Value™: HK$2.12 vs. price of HK$1.38 (34.9% below fair value)
No single metric tells the full story. See the HKSE:01302 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for HKSE:01302
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01302 has been successfully added to your 
